Tirzepatide Constipation: Why It Happens and How to Get Relief

Constipation is one of the most common — and most under-discussed — side effects of tirzepatide (sold as Zepbound for obesity and Mounjaro for type 2 diabetes). Nausea gets all the attention, but for a meaningful share of people the bigger daily nuisance is a slowed, sluggish gut. The good news: unlike some of tirzepatide's rarer warnings, constipation is well understood, it is a recognized adverse reaction on the FDA label rather than anecdote, and it usually responds to straightforward measures. This guide explains why it happens, what actually helps, and the handful of symptoms that mean you should stop managing it at home and call a clinician.

How common is it? The label number

Constipation is not a fringe complaint — it is on the FDA label. In Zepbound's pooled obesity trials, constipation was reported in roughly 11% to 17% of users across the maintenance doses, versus about 5% on placebo¹. That places it among the top handful of tirzepatide side effects, behind nausea and diarrhea but ahead of most others. Notably, the label table shows constipation skewing somewhat more common at the lower doses — a reminder that slowed gut motility cuts both ways and is present from early in treatment, not only at the top of the dose ladder¹. Systematic reviews of the tirzepatide trial program place these gastrointestinal effects firmly in the mild-to-moderate band for most people, while confirming they are dose-related and a genuine class effect²⁵.

Why tirzepatide causes constipation

The mechanism is the same one that makes tirzepatide work for weight loss, turned in an uncomfortable direction. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and one of its core actions is slowing gastric emptying — food leaves your stomach more slowly, which prolongs fullness and blunts appetite³⁴. A pharmacology study measuring gastric emptying directly confirmed tirzepatide transiently delays it, much like the long-acting GLP-1 drugs³.

That same slowing extends downstream through the gut. When transit through the intestines slows, stool spends longer in the colon, more water is reabsorbed from it, and the result is harder, less frequent, harder-to-pass bowel movements — the textbook picture of constipation. Two other tirzepatide-linked factors compound it: appetite suppression often means people eat less total food and less fiber, and the drug's tendency to reduce thirst and fluid intake can leave the colon working with less water to soften stool. So the constipation is partly the drug acting directly on motility and partly a knock-on effect of eating and drinking less — which is useful, because the second part is the part you can most readily fix.

What actually helps: evidence-based relief

Here is where honesty matters. The specific advice below is drawn from the general evidence base for treating constipation — it has not been tested in dedicated tirzepatide trials, so think of it as well-grounded clinical practice applied to a drug-induced cause, not a trial-proven protocol for this exact situation. With that caveat, the measures that have the best evidence for constipation generally are also the most sensible first steps here.

Fluids and movement first. Because reduced intake is part of the picture, deliberately drinking more water and staying physically active are the simplest levers. These are low-risk and address the dehydration-and-inactivity contribution directly.

Fiber — but build it slowly. Soluble fiber supplementation (such as psyllium) has reasonable evidence for improving stool frequency and consistency in chronic constipation in the general population⁶⁷. The caveat specific to tirzepatide: adding a lot of fiber to a gut that is already emptying slowly can backfire and worsen bloating or fullness, so increase fiber gradually and pair it with more fluid. Fiber helps when the colon can still move things along; it is less useful, and can be counterproductive, if transit is severely slowed.

Osmotic laxatives when diet isn't enough. When fluids, movement, and fiber aren't sufficient, an over-the-counter osmotic laxative is the usual next step. Polyethylene glycol (PEG, e.g. MiraLAX) has strong systematic-review support for chronic constipation and is generally first-line among over-the-counter options⁸; a Cochrane review found PEG outperformed lactulose on stool frequency and the need for additional products⁹. These draw water into the colon to soften stool and are well suited to the slowed-transit pattern tirzepatide produces. Stimulant laxatives can be used short-term but are generally a step beyond osmotics.

Always loop in your prescriber. Before starting any laxative routine — especially if you take other medications or have kidney issues — clear it with the clinician managing your tirzepatide. They can also tell you whether holding a dose increase to let your gut adapt makes sense, which the slow four-week-per-step dose ladder is partly designed to allow¹. For the full logic of the dose ladder and how it keeps GI effects manageable, see our tirzepatide dosing ladder and side effects guide.

Does it get better over time?

Partly. The acute gastrointestinal effects of tirzepatide — nausea, vomiting, loose stools — are most intense right after each dose increase and tend to ease over the following days to a couple of weeks as the gut adapts²⁵. Constipation can behave a little differently. Because it stems from ongoing slowed motility rather than an acute reaction, it is one of the side effects that can persist across maintenance dosing for some people and may need ongoing management — fiber, fluids, and occasionally an osmotic laxative — rather than simply waiting it out. For the realistic timeline of which tirzepatide side effects fade and which don't, see how long do Zepbound side effects last.

When constipation is a red flag

Most tirzepatide constipation is a manageable nuisance. But a few patterns are not, and they overlap with the drug's more serious labeled warnings, so they deserve prompt medical attention rather than another dose of laxative:

• •Severe or worsening abdominal pain, especially if persistent or radiating to the back — this can be a sign of pancreatitis or other serious abdominal problems flagged on the label, not ordinary constipation¹.
• •No bowel movement for several days combined with vomiting, a distended abdomen, or inability to pass gas — possible signs of a bowel obstruction or ileus, which is a medical emergency.
• •Blood in the stool, severe rectal pain, or unintended worsening despite treatment.
• •Constipation alternating with the dehydration risk the label warns about — severe vomiting or diarrhea on tirzepatide can cause acute kidney injury, and the broader picture matters¹; see tirzepatide and your kidneys.

Ordinary constipation that responds to fluids, fiber, and an osmotic laxative is not dangerous. It is the combination of constipation with severe pain or obstruction symptoms that warrants a call.

The honest bottom line

Constipation affects roughly 11–17% of tirzepatide users and is a recognized adverse reaction on the FDA label, not an anecdote¹. It happens because tirzepatide slows gastric emptying and gut transit — the same mechanism that drives its appetite effect — compounded by eating and drinking less³⁴. The first-line fixes are well-grounded even if not tirzepatide-specific: more fluids, more movement, fiber added slowly, and an osmotic laxative like PEG when needed, all cleared with your prescriber⁸⁹. It can persist more than the acute GI effects do, so plan to manage it rather than just wait it out. And know the red flags — severe abdominal pain or signs of obstruction are not constipation to push through, but reasons to call a clinician¹. For the full side-effect picture, see our Zepbound side effects breakdown and the tirzepatide evidence guide; to weigh your options for getting it, start with our best tirzepatide overview.